Patents Assigned to British Columbia Cancer Agency Branch
-
Patent number: 8673884Abstract: The present invention provides pyrimidinyl compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be used for the inhibition of influenza. In particular, the compounds of the invention may be used for the treatment or prophylaxis of influenza A, most particularly H1N1 or H5N1 influenza. The compounds of the invention can also be used for the treatment or prophylaxis of a disease caused by Vibrio cholerae, Clostridium perfringens, Streptococcus pneumoniae, Arthrobacter sialophilus, an orthomyxovirus, a paramyxovirus, a parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague virus or Sendai virus.Type: GrantFiled: February 4, 2009Date of Patent: March 18, 2014Assignees: Versitech Limited, British Columbia Cancer Agency BranchInventors: Steven J. Jones, Allan Sik-Yin Lau, Jianghong An, Hing Yee Law, Chun Wai Davy Lee, Lit Man Poon
-
Publication number: 20140066862Abstract: Ergonomic syringe systems provide attachments that may be used to allow users to dispense or draw in fluid with increased operator comfort and reduced risk of repetitive strain injuries. The disclosure describes supports for holding syringes that permit one-handed operation, handles that are removably attachable to syringe plungers and hand supports that are removably attachable to syringe barrels.Type: ApplicationFiled: May 18, 2012Publication date: March 6, 2014Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Thomas Lloyd BELLAIRE, Dennis SCHWEERS, Richard HALL, Brian KEANE
-
Publication number: 20140023993Abstract: A multiphoton microscope is provided. The microscope includes: an excitation source for providing an optical excitation beam at an excitation wavelength ?; a scanner for scanning the excitation beam on a sample; an objective for irradiating the sample with the excitation beam scanned by the scanner and for collecting an emission beam from the sample; a first detector for detecting a plurality of multiphoton signals; and an emission light path allowing transmission from the objective to the first detector a wavelength band limited to greater than or equal to ?/2 and less than ?, wherein the plurality of multiphoton signals have wavelengths within the wavelength band; wherein the plurality of multiphoton signals comprises a first multiphoton signal and a second multiphoton signal of different types. Fast image capture rate multiphoton microscopes for in vivo imaging, as well as photothermolysis methods using the microscopes are also provided.Type: ApplicationFiled: April 5, 2012Publication date: January 23, 2014Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Haishan Zeng, Harvey Lui, David McLean, Anthony Lee, Hequn Wang, Shuo Tang
-
Publication number: 20130336962Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: April 16, 2013Publication date: December 19, 2013Applicants: The University of Biritish Columbia, British Columbia Cancer Agency BranchInventors: British Columbia Cancer Agency Branch, The University of British Columbia
-
Patent number: 8559693Abstract: Systems and methods for the quantitative automated analysis of pathology samples identify groups of spatially-associated similar cells. Cells may be identified as belonging to a group on the basis of spatial location and biomarkers. In some embodiments the biomarkers are multicolour fluorescence in situ hybridization (FISH) signals. Characteristics of the cells in a group may be combined to provide quantitative FISH results that may compensate for variations and artefacts such as thin sectioning that can result in the loss of information due to damage. In heterogeneous tissue samples, grouping cells can permit quantitative results regarding pathological cells to be extracted despite the presences of infiltrating non pathological cells.Type: GrantFiled: October 10, 2008Date of Patent: October 15, 2013Assignees: British Columbia Cancer Agency Branch, The University of British ColumbiaInventors: Calum Eric MacAulay, Piotr Dubrowski, Martial Guillaud, Mehrnoush Khojasteh
-
Publication number: 20130245129Abstract: This invention provides compound having a structure of Formula I or Formula II Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: April 19, 2013Publication date: September 19, 2013Applicants: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Marianne D. Sadar, Nasrin R. Mawji, Jun Wang, Raymond J. Andersen, David E. Williams, Mike Leblanc
-
Publication number: 20130231573Abstract: Near-infrared Raman spectroscopy can be applied to identify preneoplastic lesions of the bronchial tree. Real-time in vivo Raman spectra of lung tissues may be obtained with a fiber optic catheter passed down the instrument channel of a bronchoscope. Using prototype apparatus, preneoplastic lesions were detected with sensitivity and specificity of 96 and 91% respectively. The use of Raman spectroscopy apparatus and methods in conjunction with other bronchoscopy imaging modalities can substantially reduce the number of false positive results.Type: ApplicationFiled: January 21, 2011Publication date: September 5, 2013Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Haishan Zeng, Michael Short, Stephen Lam, Annette McWilliams
-
Publication number: 20130209402Abstract: The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same.Type: ApplicationFiled: July 15, 2011Publication date: August 15, 2013Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: John R. Webb, Darin Arne Wick
-
Publication number: 20130197056Abstract: Novel biomarkers and targets associated with ovarian cancer, particularly clear-cell carcinoma, endometrioid carcinoma, and uterine carcinoma, are disclosed. Mutations in genes encoding proteins that form part of the SWI/SNF chromatin remodelling protein complex, including ARID1A, or loss of expression of such proteins, including BAF250a, can be used to evaluate the likelihood endometriosis will progress or transform to cancer, to provide a prognosis for a patient with cancer, to assess whether conventional treatment is likely to be effective against a cancer, and/or in a synthetic lethal screen to identify novel targets and therapeutics for the treatment of cancer.Type: ApplicationFiled: April 22, 2011Publication date: August 1, 2013Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: David G. Huntsman, Marco Marra, Kimberly Wiegand, Martin Hirst, Sohrab Prakash Shah
-
Publication number: 20130195843Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.Type: ApplicationFiled: March 15, 2013Publication date: August 1, 2013Applicant: British Columbia Cancer Agency BranchInventor: British Columbia Cancer Agency Branch
-
MULTIMODAL DETECTION OF TISSUE ABNORMALITIES BASED ON RAMAN AND BACKGROUND FLUORESCENCE SPECTROSCOPY
Publication number: 20130131488Abstract: Methods and apparatus for classifying tissue use features of Raman spectra and background fluorescent spectra. The spectra may be acquired in the near-infrared wavelengths. Principal component analysis and linear discriminant analysis of reference spectra may be used to obtain a classification function that accepts features of the Raman and background fluorescence spectra for test tissue and yields an indication as to the likelihood that the test tissue is abnormal. The methods and apparatus may be applied to screening for skin cancers or other diseases.Type: ApplicationFiled: November 7, 2012Publication date: May 23, 2013Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventor: BRITISH COLUMBIA CANCER AGENCY BRANC -
Publication number: 20130131167Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.Type: ApplicationFiled: January 6, 2011Publication date: May 23, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130109758Abstract: This invention provides compounds having a structure of Formula (I). Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: January 6, 2011Publication date: May 2, 2013Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
-
Publication number: 20130065789Abstract: The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application.Type: ApplicationFiled: November 8, 2012Publication date: March 14, 2013Applicants: BRITISH COLUMBIA CANCER AGENCY BRANCH, UNIVERSITY HEALTH NETWORKInventors: University Health Network, British Columbia Cancer Agency Branch
-
Publication number: 20130045204Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.Type: ApplicationFiled: August 17, 2012Publication date: February 21, 2013Applicants: The University of British Columbia, British Columbia Cancer Agency BranchInventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Carmen Adriana Banuelos, Nasrin Mawji, Jun Wang
-
Publication number: 20130004482Abstract: The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective.Type: ApplicationFiled: March 15, 2012Publication date: January 3, 2013Applicants: The University of North Carolina at Chapel Hill, British Columbia Cancer Agency Branch, University of Utah Research Foundation, Washington UniversityInventors: Charles M. Perou, Matthew J. Ellis, Philip S. Bernard, Torsten O. Nielsen
-
Multimodal detection of tissue abnormalities based on raman and background fluorescence spectroscopy
Patent number: 8326404Abstract: Methods and apparatus for classifying tissue use features of Raman spectra and background fluorescent spectra. The spectra may be acquired in the near-infrared wavelengths. Principal component analysis and linear discriminant analysis of reference spectra may be used to obtain a classification function that accepts features of the Raman and background fluorescence spectra for test tissue and yields an indication as to the likelihood that the test tissue is abnormal. The methods and apparatus may be applied to screening for skin cancers or other diseases.Type: GrantFiled: November 26, 2004Date of Patent: December 4, 2012Assignee: British Columbia Cancer Agency BranchInventors: Haishan Zeng, Harvey Lui, Zhiwei Huang, David I. McLean -
Publication number: 20120301891Abstract: There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-?3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1?), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-?3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1?, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.Type: ApplicationFiled: August 10, 2012Publication date: November 29, 2012Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Yuanmei LOU, Paul Christopher MCDONALD, Arusha OLOUMI, Shoukat DEDHAR
-
Publication number: 20120259229Abstract: A micro-Raman spectrometer system for use in differentiating tumor lesions from normal skin detects specific characteristics of Raman spectra indicative of cancer. A peak at 899 cm?1 and a higher intensity region in the 1325 cm?1 to 1330 cm?1 range indicate the presence of tumors. The spectrometer system may be applied for skin cancer detection and for mapping the margins of lesions. Cancer detection methods as described herein have achieved diagnostic sensitivity of 95.8% and specificity of 93.8%.Type: ApplicationFiled: December 17, 2010Publication date: October 11, 2012Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: Hequn Wang, Haishan Zeng, Harvey Lui, Jianhua Zhao
-
Publication number: 20120225793Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Applicants: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on Behalf of the University of Arizona, Universitat De Barcelona, Queen Mary and Westfield College, University of London, Hospital Clinic, Julius-Maximilians-University of Wuerzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HE, Fundacio ClinicInventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa Rimsza, Thomas Miller, Thomas Grogan, Elias Campo, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emili Montserrat, Victor Moreno, Andreas Zetti, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister